Why is diabetes an imperfect science? The last 22 years of my life with diabetes have disproved as much (or more) than it has confirmed in conventional diabetes wisdom. The facts were in the studies - but researchers didn't know what to do with them, at the time. Here's where the mysteries will unfold..

The last year blogging with The Diabetes Blog has been an in your face demonstration of the imperfect science of diabetes. Many undisclosed details of studies from days gone by have proven to be a reason why diabetes has been an imperfect science. Since when has science been imperfect? When you don't complete your homework. Don't get wrong - science has done the homework, but you - the diabetic - have not been privy to every fact found in these studies. Nowadays, there's no excuse. The dog doesn't eat my homework.

It's time these facts made it to the light of day. I am taking my investigative curiosity and hanging a shingle over LoveDiabetes.com - because that's who I am: Allison Love Beatty! Let's buddy-up with the researchers and their homework. It's about time we solved the universal mysteries of diabetes. The facts are available. With combined knowledge, existential and pathological, we can make more of these studies from yesteryear and the days to come.

Someday soon we will see the trend of diabetes reverse - less diagnosis, less complications, and reduced costs. I've got Internet access, unlimited long-distance, and plenty of time. The fun is just getting started! This is my invitation to you - what's your diabetes mystery? Leave me a comment on LoveDiabetes.com so I know what's on your mind. Together we will prove there is no such a thing as an imperfect science.

Love always,
Allie B

The scientists at University of Pennsylvania School of Medicine discovered that it is possible to regenerate damaged cells of the pancreas. Although the cells that revealed this discovery are not the beta cells of the pancreas, researchers believe that this research could find new ways to replenish the organs ability to produce insulin in diabetics.

The pancreas is made up of two compartments with different functions: the islet compartment of insulin-producing beta cells and the much larger exocrine compartment composed of duct cells and acinar cells that make and deliver enzymes to the intestine for digestion. Diabetes is caused by the failure of the beta cells to make insulin, whereas pancreatic cancer usually originates from the exocrine compartment. Under certain conditions in tissue culture, acinar cells can synthesize insulin as well as amylase, a digestion enzyme.

Evidence from this research is pointing to the beta cell itself as the most promising source for generating new beta cells. The focus of research is now shifting toward the direct stimulation of islet cell growth in live animals. In contrast, once acinar cells are removed from the organism and placed into culture, they may have greater potential to change into other cell types, including beta cells. As a result, Stoffers' animal model and technical approach is currently being used by other groups in the United States, Europe, and China to determine conditions under which acinar cells can take on the features of duct cells and beta cells.

Generex has been awarded the 2006 North American Frost & Sullivan Award for Technology Innovation for its proprietary oral insulin spray product, Generex Oral-lyn.

Frost & Sullivan's Technology Innovation Award is bestowed upon a company (or individual) that has carried out new research, which has resulted in innovation(s) that have or are expected to bring significant contributions to the industry at hand. In this case, Frost & Sullivan is awarding Generex Oral-lyn as a product that is strongly positioned to be the most acceptable form of alternative, needle-free insulin delivery. This award recognizes the quality and depth of Generex's research and development program as well as the vision and risk-taking that enabled it to undertake such an endeavor.

The significance of Oral-lyn is growing in importance because of its ability to control blood sugar rises after meals. There is mounting evidence that post meal glucose control is a key factor in reducing cardiovascular risk associated with diabetes. For those who keep asking - the CFO has informed me that they are looking into other options that will get Oral-lyn into the hands (and mouths) of US diabetics by sometime in 2007.